A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS-101 in Hematological Malignancies
This clinical trial a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of the novel drug, VLS-101. The trial is assessing VLS-101 monotherapy across a range of dose levels when administered to patients with previously treated hematologic cancers. More details are available at ClinicalTrials.gov or by contacting us.
A Phase 2 Study of VLS-101 in Patients with Solid Tumors
This clinical trial is a Phase 2 study evaluating the efficacy, safety, pharmacokinetics, immunogenicity, and pharmacodynamics of VLS-101 in patients with metastatic solid tumors. Accrual of subjects with any of the following tumor types is planned: previously treated triple-negative breast cancer; previously treated hormone receptor-positive and/or HER2-positive breast cancer; and previously treated non-squamous, non-small-cell lung cancer. More details are available at ClinicalTrials.gov or by contacting us.
VelosBio Inc. is now a wholly-owned subsidiary of Merck & Co., Inc. (Kenilworth, New Jersey USA)